Do you want to read an article? Please log in or register.
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
Type 2 Diabetes
COMMENTED
Related content
Type 2 Diabetes
Sodium-glucose Cotransporter 2 Inhibitors and the Risk for Urosepsis - A Multi-site Prevalent New-user Cohort Study
Diabetes Obes Metab.
Fisher A, Fralick M, Filion KB, Dell'Aniello S, Douros A, Tremblay É, Shah BR, Ronksley PE, Alessi-Severini S, Hu N, Bugden SC, Ernst P, Lix LM, Canadian Network for Observational Drug Effect Studies (CNODES).
doi: 10.1111/dom.14082.
COMMENTED
Diabetes - GeneralType 2 Diabetes
Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes
JAMA Intern Med.
Chang HY, Singh S, Mansour O, Baksh S, Alexander GC
doi: 10.1001/jamainternmed.
Type 2 Diabetes
Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study
Diabetes Obes Metab.
Birkeland KI, Bodegard J, Banerjee A, Kim DJ, Norhammar A, Eriksson JW, Thuresson M, Okami S, Ha KH, Kossack N, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T
doi: 10.1111/dom.14189.
COMMENTED
Type 2 Diabetes
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden
Lancet Diabetes Endocrinol.
Svanström H, Ueda P, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B
doi: 10.1016/S2213-
COMMENTED
Type 2 Diabetes
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M, CVD-REAL 2 Investigators and Study Group
doi: 10.1016/S2213-8587(20)30130-3.
COMMENTED
Diabetic Complications
Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71,553 Individuals
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
J Clin Endocrinol Metab
Lin DS, Lee JK, Chen WJ
doi: 10.1210/clinem/dgab274
COMMENTED
Type 2 Diabetes
Evolving evidence of diabetic ketoacidosis in patients taking sodium glucose cotransporter 2 inhibitors
doi: 10.1210/clinem/dgaa200.
COMMENTED
Diabetes - GeneralType 2 DiabetesGlycemic Control
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis
JAMA.
Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K
doi: 10.1001/jama.2018.3024.
Type 2 Diabetes
Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis
Diabet Med.
Hussein H, Zaccardi F, Khunti K, Seidu S, Davies MJ, Gray LJ
doi: 10.1111/dme.